CATB - Catabasis Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 580.84M
Enterprise Value 332.03M
Trailing P/E N/A
Forward P/E 1-3.04
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)N/A
Price/Book (mrq)1.62
Enterprise Value/Revenue 3N/A
Enterprise Value/EBITDA 6-1.33

Trading Information

Stock Price History

Beta (3Y Monthly) 1.54
52-Week Change 32.00%
S&P500 52-Week Change 34.88%
52 Week High 39.76
52 Week Low 33.60
50-Day Moving Average 37.04
200-Day Moving Average 36.76

Share Statistics

Avg Vol (3 month) 388.87k
Avg Vol (10 day) 339.1k
Shares Outstanding 5N/A
Float 10.89M
% Held by Insiders 11.87%
% Held by Institutions 133.18%
Shares Short (Jun 28, 2019) 4615.26k
Short Ratio (Jun 28, 2019) 46.31
Short % of Float (Jun 28, 2019) 45.45%
Short % of Shares Outstanding (Jun 28, 2019) 45.35%
Shares Short (prior month May 31, 2019) 4592.93k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 210/1
Last Split Date 3Dec 31, 2018

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Mar 31, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-41.50%
Return on Equity (ttm)-77.25%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -24.1M
Net Income Avi to Common (ttm)-24.26M
Diluted EPS (ttm)-3.56
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)51.66M
Total Cash Per Share (mrq)4.49
Total Debt (mrq)1.59M
Total Debt/Equity (mrq)3.19
Current Ratio (mrq)12.25
Book Value Per Share (mrq)4.34

Cash Flow Statement

Operating Cash Flow (ttm)-23.23M
Levered Free Cash Flow (ttm)-14.04M